Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Neon Therapeutics

Neon Therapeutics?uq=PEM9b6PF
2013 FOUNDED
PUBLIC STATUS
81-90 EMPLOYEES
NTGN STOCK SYMBOL
$5.57 SHARE PRICE (As of Friday Closing)
Description

Developer of neoantigen-targeted therapies designed to treat cancer by directing the immune system towards neoantigens. The company develops next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens thus significantly improving the lives of patients.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 40 Erie Street
  • Suite 110
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neon Therapeutics’s full profile, request a free trial.

Neon Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.50 - $15.00 $156M $5.50 -$6.23 161K 28.3M

Neon Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 103,072
Revenue 0
EBITDA (68,254) (47,185) (27,022)
Net Income (68,287) (47,536) (27,433)
Total Assets 132,579 90,493 95,261
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neon Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.

Request full access to PitchBook

Neon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Neon Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Neon Therapeutics‘s full profile, request access.

Request full access to PitchBook

Neon Therapeutics Executive Team (16)

Name Title Board
Seat
Contact
Info
Hugh O'Dowd Chief Executive Officer, President & Board Member
Richard Gaynor President, Research & Development
Yasir Al-Wakeel Chief Financial Officer
Ed Fritsch Ph.D Co-Founder & Chief Technology Officer
Eric Lander Ph.D Scientific Partner & Board Member

3 Former Executives

You’re viewing 5 of 16 executives. Get the full list »

Neon Therapeutics Board Members (8)

Name Representing Role Since Contact
Info
Cary Pfeffer MD Third Rock Ventures Chairman 000 0000
Eric Lander Ph.D Neon Therapeutics Scientific Partner & Board Member 000 0000
Hugh O'Dowd Neon Therapeutics Chief Executive Officer, President & Board Member 000 0000
Julian Adams Ph.D Clal Biotechnology Industries Board Member 000 0000
Meryl Zausner Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »